Source: streetinsider

Press Release: Karyopharm : Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 428,500 shares of Karyopharm’s common stock to eighty-three newly-hired employees, with a grant date of January 31, 2019. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4).

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Karyopharm's latest SEC filings

Annual Revenue

Based on data from Karyopharm's latest SEC filings

Employees

Michael G. Kauffman's photo - Co-Founder & CEO of Karyopharm

Co-Founder & CEO

Michael G. Kauffman

CEO Approval Rating

68/100

Karyopharm researches and develops therapeutics for the treatment of cancer.

Karyopharm's headquarters is in Newton, Mass...
Read more